News | June 02, 2025
Sanofi acquires US biopharma firm Blueprint Medicines for $9.1 billion
Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio
Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio
This expanded partnership helps Evonik to streamline its distribution model in Asia Pacific
First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
Seamless transition from preclinical to first-in-human trials with EUDRACAP platform technology
In animal health, the products will be mainly targeting mastitis and production disorders, gastrointestinal tract diseases, reproductive disorders, ectoparasites, and skin injuries
Subscribe To Our Newsletter & Stay Updated
